Cardinal Health raised its annual outlook again after logging higher profit and revenue in its fiscal second quarter.

The team remains focused on driving Cardinal Health brand growth, where we continue to see positive results and ...

Shares of Cardinal Health Inc. rallied 9.83% to $227.18 Thursday, on what proved to be an all-around grim trading session for ...

Cardinal Health (NYSE: CAH) delivered a decisive second-quarter beat on February 5, 2026, with non-GAAP EPS of $2.63, ...

Cardinal Health has reported that revenue for its Other segment, which includes at-Home Solutions, increased 34% to $1.7 ...

Cardinal Health reports strong Q2 results and raises fiscal 2026 outlook. Sales increased by 19%, beating estimates.

New NAHR Fellow and retiring CHRO Ola Snow of Cardinal Health says investment in culture has been critical to the ...

Cardinal Health, Inc. (NYSE:CAH) supplies branded, generic, and specialty medicines and provides pharmacy and specialty drug ...

Pharmaceutical distributor Cardinal Health is eyeing an expanded footprint in the specialty medicine space through the planned acquisitions of GI Alliance (GIA) and Advanced Diabetes Supply Group (DSG ...

Robust demand across its pharmaceutical and specialty solutions segment was the impetus behind Cardinal Health raising its fiscal 2025 enterprise guidance, said Jason Hollar, CEO of Cardinal Health, ...

Cardinal Health (CAH) upgraded to Buy after a 100%+ run—see FY26 guidance, acquisitions, and nuclear medicine catalysts, plus ...

Cardinal Health (CAH) closed at $210.93 in the latest trading session, marking a +1.25% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.5%. At the same time, the Dow added 0.